Background: Tivantinib is a selective MET inhibitor that is extensively metabolized in the liver. In a randomized, placebo-controlled phase 2 study in patients with advanced HCC, tivantinib monotherapy improved time to progression by 56%. However, in that study at the standard phase 2 dose of 360 mg twice-daily (BID), tivantinib exposure was increased, and the […]
